EcoDrugPlus

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSMLUG00000014981
Gene Symbol: PDGFB
2 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSMLUG00000012154
Gene Symbol: PLK1
2 Cross references
183 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSMLUG00000005379
Gene Symbol: PLK4
2 Cross references
208 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSMLUG00000012285
Gene Symbol: PARP1
2 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSMLUG00000015313
Gene Symbol: PARP2
2 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSMLUG00000007900
Gene Symbol: PARP3
2 Cross references
198 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSMLUG00000003981
Gene Symbol: PORCN
2 Cross references
263 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSMLUG00000005723
Gene Symbol: KCNMA1
2 Cross references
284 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSMLUG00000012273
Gene Symbol: KCNJ11
2 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSMLUG00000006713
Gene Symbol: KCNJ2
2 Cross references
277 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSMLUG00000010559
Gene Symbol: KCNJ3
2 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSMLUG00000005241
Gene Symbol: KCNJ5
2 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).